Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.
Qlife commences trading on Nasdaq First North Growth Market
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm. Qlife Holding AB (“Qlife”) belongs to the health care sector and is the 6[th] company to be admitted to trading on Nasdaq’s Nordic markets* in 2020.
Qlife (https://qlifeholding.com/sv/home) is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most. Its main product, The Egoo Home System, is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer. Qlife is headquartered in Helsingborg, Sweden.
“Today is a big milestone for Qlife. Going public has been a journey that would not have been possible if not for the incredible, dedicated team behind Qlife,” said Thomas Warthoe, CEO of Qlife. “I am humbled by the level of interest from investors who can see the same potential in Qlife as we do, and for how they want to help us help others. I am looking forward to developing the company together with my team and create value for customers and investors. There is no doubt that the real journey has just begun.”
“We welcome Qlife to the Nasdaq First North Growth Market,” said Adam Kostyál, SVP and Head of European Listings, Nasdaq. “We continue to see an inflow of innovative health care companies leveraging the Nasdaq First North Growth Market as a platform for growth, and we look forward to supporting Qlife on its continued journey as a publicly listed company.”
Qlife Holding AB has appointed G&W Fondkommission as the Certified Adviser.
*Main markets and the Nasdaq First North Growth Market at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm.
The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.
The Egoo Home System is an integrated platform consisting of a small device, disposable capsules, each a test for a specific biomarker, and a digital infrastructure that can share data with patient
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Stockholm on 25 November.
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November.
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier.
Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment